The next dose of Wegovy after 0.25mg, and why the schedule is built the way it is

What the licensed titration schedule actually says

The Wegovy schedule was designed with the trial evidence in mind. In the STEP 1 study (published in the New England Journal of Medicine and involving nearly 2,000 adults with obesity) participants followed a structured escalation from 0.25mg to the 2.4mg maintenance dose over roughly 16 weeks. That structure matters because the GI side effects most people experience (nausea, loose stools, indigestion) are most pronounced early in treatment and after each step up. Slow titration is what keeps those effects manageable for most people.

After 0.25mg, the schedule moves to 0.5mg for the next four weeks, and knowing what comes after that helps you plan the full titration journey ahead. Then 1.0mg. Then 1.7mg. Then 2.4mg as the standard maintenance dose. Each rung represents about a month of treatment. The NHS semaglutide medicines page sets out this progression in plain language, and it is the schedule your prescriber will follow when reviewing whether to move you forward.

One practical note on timing: if your four-week supply runs out around a bank holiday or your usual order date falls on a Monday, plan ahead. The titration clock doesn't pause, and a gap of more than a couple of days before your next injection is worth flagging to your prescriber rather than simply skipping to the next strength.

Why 0.25mg is not a weight-loss dose

This is a question our prescribers hear regularly, and it's worth being direct about it. The 0.25mg starting pen delivers far less semaglutide than the doses shown to produce meaningful average weight loss in trials. Its purpose is adjustment, letting the body's GLP-1 receptors respond to the medicine before a larger amount arrives. For most people, appetite suppression at this stage is modest, and that's expected.

The full dose range for Wegovy only reaches its clinical effect at and above 1.7mg, with 2.4mg being where the STEP 1 data were generated. Patients who stay at 0.25mg for longer than intended (through a delivery delay, a prescription lapse, or uncertainty about when to move up) often feel the medicine isn't working. In most cases, it's simply that they haven't yet reached a therapeutic level.

This is also why the transition between each Wegovy dose step is a clinical review point rather than an automatic gateway. Your prescriber considers tolerance, any side effects, and your overall health picture before confirming the step to 0.5mg.

Side effects to expect when moving from 0.25mg to 0.5mg

Moving up to 0.5mg is where some people first notice a meaningful change in appetite, and also where GI symptoms can tick up temporarily. Nausea is the most commonly reported effect; vomiting, constipation, and reflux follow behind it. For most patients, these settle within the first week or two at the new dose and do not persist at the same intensity.

If side effects at 0.5mg are significant, a prescriber may recommend staying at that level for longer than four weeks before the next step. That is not a failure; it is how the schedule is supposed to flex. Rushing the titration does not produce better results and typically produces worse tolerability.

One set of symptoms warrants urgent attention at any dose: severe, persistent abdominal pain that radiates toward the back, with or without vomiting, could indicate pancreatitis, a rare but serious effect highlighted in an MHRA Drug Safety Update. If that pattern develops, stop the medicine and seek medical help promptly rather than waiting for your next scheduled review. You can also report suspected side effects via the MHRA Yellow Card scheme.

The step from 0.5mg to 1.0mg follows the same pattern, a month at the new level, a prescriber review, and tolerance assessed before progressing.

Getting your next dose through a private prescriber

Wegovy is a prescription-only medicine. The 0.5mg pen (like every other strength) requires a valid UK prescription, and that prescription comes from a clinician who has reviewed your health information, not from a checkout page. If you're exploring what Wegovy costs privately, knowing that a legitimate price always includes clinical oversight is the first thing to check.

At nume, a GPhC-registered Independent Prescriber reviews every consultation the same day, a real clinician reads your answers and makes the decision, not software. For context on how our pharmacy operates, our about page explains who we are and how the service is structured. If you're at the 0.25mg stage and ready to discuss your next step, checking your eligibility is the starting point.